SG11201507361YA - Combination of direct acting antiviral agents and ribavirin for treating hcv patients - Google Patents
Combination of direct acting antiviral agents and ribavirin for treating hcv patientsInfo
- Publication number
- SG11201507361YA SG11201507361YA SG11201507361YA SG11201507361YA SG11201507361YA SG 11201507361Y A SG11201507361Y A SG 11201507361YA SG 11201507361Y A SG11201507361Y A SG 11201507361YA SG 11201507361Y A SG11201507361Y A SG 11201507361YA SG 11201507361Y A SG11201507361Y A SG 11201507361YA
- Authority
- SG
- Singapore
- Prior art keywords
- ribavirin
- combination
- antiviral agents
- direct acting
- treating hcv
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 title 1
- 229960000329 ribavirin Drugs 0.000 title 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507361YA true SG11201507361YA (en) | 2015-10-29 |
Family
ID=50771575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507361YA SG11201507361YA (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
| SG10201709840UA SG10201709840UA (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201709840UA SG10201709840UA (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (enExample) |
| EP (4) | EP3318258B1 (enExample) |
| JP (3) | JP6563894B2 (enExample) |
| KR (2) | KR20180045055A (enExample) |
| CN (3) | CN109908353A (enExample) |
| AU (3) | AU2014239322B2 (enExample) |
| BR (1) | BR112015020918A2 (enExample) |
| CA (1) | CA2901818C (enExample) |
| CY (1) | CY1121474T1 (enExample) |
| DK (1) | DK2968302T3 (enExample) |
| EA (2) | EA030482B1 (enExample) |
| ES (1) | ES2654109T3 (enExample) |
| HK (1) | HK1255257A1 (enExample) |
| HR (1) | HRP20171898T1 (enExample) |
| HU (1) | HUE036069T2 (enExample) |
| IL (2) | IL240445B (enExample) |
| LT (1) | LT2968302T (enExample) |
| MX (1) | MX2015012536A (enExample) |
| NO (1) | NO3090119T3 (enExample) |
| PL (1) | PL2968302T4 (enExample) |
| PT (1) | PT2968302T (enExample) |
| RS (1) | RS56735B1 (enExample) |
| SG (2) | SG11201507361YA (enExample) |
| SI (1) | SI2968302T1 (enExample) |
| SM (1) | SMT201800017T1 (enExample) |
| TW (2) | TWI678205B (enExample) |
| WO (1) | WO2014152635A1 (enExample) |
| ZA (1) | ZA201705080B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| EP3318258B1 (en) | 2013-03-14 | 2020-05-13 | AbbVie Inc. | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
| CN105658219A (zh) * | 2013-10-25 | 2016-06-08 | 艾伯维公司 | 用于治疗hcv的方法 |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| CA2943054A1 (en) * | 2014-04-02 | 2015-10-08 | Abbvie Inc. | Methods for treating hcv |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| EP3383662B1 (en) | 2016-01-08 | 2020-09-02 | Entrust Datacard Corporation | Card printing mechanism with card return path |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| MA46292A (fr) * | 2016-09-23 | 2019-07-31 | Abbvie Inc | Réglage de dose |
| CA2994496A1 (en) * | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| CN112351799A (zh) * | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011522862A (ja) * | 2008-06-10 | 2011-08-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法 |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| EP2853531A3 (en) * | 2009-06-11 | 2015-08-12 | AbbVie Bahamas Ltd. | Antiviral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| TWI523658B (zh) * | 2010-09-21 | 2016-03-01 | 安塔製藥公司 | 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑 |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| EP3318258B1 (en) | 2013-03-14 | 2020-05-13 | AbbVie Inc. | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
-
2014
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko not_active Abandoned
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 SM SM20180017T patent/SMT201800017T1/it unknown
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 PL PL14725812T patent/PL2968302T4/pl unknown
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en not_active Ceased
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko not_active Expired - Fee Related
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267927A (en) | A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients | |
| IL285646A (en) | Combined treatment includes mdm2 inhibitor and decitabine or cytrabine to treat AML | |
| IL264541B (en) | The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b | |
| IL240213A0 (en) | Sulfamoyl-arylamides and their use as drugs for the treatment of jaundice b | |
| IL242141B (en) | The history of sulfamoylthiophenamide and their use as drugs to treat jaundice b | |
| IL241110A0 (en) | n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice | |
| SG11201509048VA (en) | Tetrapeptides derived from human c-x-c chemokines useful for treatment of various skin conditions | |
| IL244035B (en) | Treatment of gases | |
| AP2015008814A0 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |